Tobias Seibel
Overview
Explore the profile of Tobias Seibel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eigentler T, Thomas I, Samoylenko I, Erdmann M, Heinzerling L, Ochsenreither S, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904560
Background: CV8102, a toll-like receptor 7/8 and RIG I agonist, has demonstrated antitumor immune responses in preclinical studies. We investigated intratumoral (IT) administration of CV8102 in patients with anti-programmed cell...
2.
Loeffler C, El Nahhas O, Muti H, Carrero Z, Seibel T, van Treeck M, et al.
BMC Biol
. 2024 Oct;
22(1):225.
PMID: 39379982
Background: Homologous recombination deficiency (HRD) is recognized as a pan-cancer predictive biomarker that potentially indicates who could benefit from treatment with PARP inhibitors (PARPi). Despite its clinical significance, HRD testing...
3.
Loeffler C, El Nahhas O, Muti H, Seibel T, Cifci D, van Treeck M, et al.
medRxiv
. 2023 Mar;
PMID: 36945540
Background: Homologous Recombination Deficiency (HRD) is a pan-cancer predictive biomarker that identifies patients who benefit from therapy with PARP inhibitors (PARPi). However, testing for HRD is highly complex. Here, we...
4.
Saldanha O, Quirke P, West N, James J, Loughrey M, Grabsch H, et al.
Nat Med
. 2022 Apr;
28(6):1232-1239.
PMID: 35469069
Artificial intelligence (AI) can predict the presence of molecular alterations directly from routine histopathology slides. However, training robust AI systems requires large datasets for which data collection faces practical, ethical...
5.
Papachristofilou A, Hipp M, Klinkhardt U, Fruh M, Sebastian M, Weiss C, et al.
J Immunother Cancer
. 2019 Feb;
7(1):38.
PMID: 30736848
Background: Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding...
6.
Klug F, Prakash H, Huber P, Seibel T, Bender N, Halama N, et al.
Cancer Cell
. 2013 Nov;
24(5):589-602.
PMID: 24209604
Inefficient T cell migration is a major limitation of cancer immunotherapy. Targeted activation of the tumor microenvironment may overcome this barrier. We demonstrate that neoadjuvant local low-dose gamma irradiation (LDI)...
7.
Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, et al.
Cancer Res
. 2009 Oct;
69(21):8420-8.
PMID: 19843863
Spontaneous immune responses in cancer patients have been described. Yet their clinical relevance and the conditions for their generation remain unclear. We characterized conditions that determine immune responses in primary...
8.
Issa Y, Nummer D, Seibel T, Muerkoster S, Koch M, Schmitz-Winnenthal F, et al.
J Mol Med (Berl)
. 2008 Oct;
87(1):99-112.
PMID: 18931829
L1 cell adhesion molecule (L1CAM) is a transmembrane cell adhesion molecule initially defined as a promigratory molecule in the developing nervous system that appears to be also expressed in some...